SCHEMBL5046882

SCHEMBL5046882

CN(C)c1ccc(Nc2cc(OC3CCNCC3)ncn2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.46
CDK2 P24941 4/20 0.42
CDK6 Q00534 2/20 0.42
CCNA2 P20248 2/20 0.42
CDK5 Q00535 2/20 0.42
CDK5R1 Q15078 2/20 0.42
CCNT1 O60563 1/20 0.42
CCND3 P30281 1/20 0.42
CDK7 P50613 1/20 0.42
CDK9 P50750 1/20 0.42
CCNH P51946 1/20 0.42
MNAT1 P51948 1/20 0.42
FLT3 P36888 3/20 0.41
EGFR P00533 4/20 0.35
FGFR1 P11362 3/20 0.35
FLT1 P17948 3/20 0.35
FLT4 P35916 3/20 0.35
KDR P35968 3/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049760 0.82 GPR119 (0.43) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL5190352 0.82 GPR119 (0.49) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL3672449 0.82 GPR119 (0.67) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL391183 0.79 GPR119 (0.75) GPR119CYP2C9
SCHEMBL5264798 0.78 GPR119 (0.41) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL4722205 0.78 GPR119 (0.59) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL5048550 0.76 GPR119 (0.49) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL4269127 0.76 CSNK2A2 (0.43) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL27747809 0.76 GPR119 (0.39) GPR119CDK2CDK6CCNA2CDK5
SCHEMBL5046883 0.76 GPR119 (0.39) GPR119CDK2CDK6CCNA2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed